Same, just being cautious now because Agora is playing their stupid game and will exit before news release. Watch for the dump/drop before July comes around that will hit a couple of new investors.
I'd be cautious about all of the pumping. This may mean that the stock will drop prior to phase 3 release due to unwarranted Adam F. and StreetSweeper bashing (like CPXX). So don't go long on margin. Just wait and go long when July comes around. Good luck.
This isn't for UTIs, so I wouldn't be too worried if comparing to TTPH. I think investors got spooked and are sitting on the sideline waiting for Phase 3. It will move upward quickly because this is a good broadspectrum.
I agree, I like that it's mispriced due to large pharma turning their attention to cancer/orphan drugs as supposed to antibiotics. The reality is there will be an antibiotic shortage. Specifically there will be a shortage of broad spectrum antibiotics. They have around 700 patient history for their lead antibiotic and so far there's been little to no signs of resistance, similar GI adverse events with good efficacy. I have no doubt that with a positive phase 3 this will be at $600-700 M. Low float, high cash reserve, and high institutional ownership. What's there not to like?
Cempra is worth $900M and their antibiotic isn't as broad as PRTK. PRTK is at $300M which makes them undervalued prior to the first Phase 3. Noting that broad spectrum antibiotics are a rare commodity there should also be a premium even if 1.5 years out.
I think min $500M cap for postive phase 3. For other indications an additional $250M+ until trials can confirm effect. Easily a buyout for a company still developing sickle cell gene therapy for revenue until gene therapy works. If the results are good enough, they'll apply for breakthrough therapy, rationale that VOCs cause cumulative organ damage. Average life span is still less than 50.
Donna what are you doing still here? Looking to load up on cheap shares? Shorting obviously would be plain dumb when it triples on the way to $500 M. Go look at CPXX board when I warned all the dumb shorts prior to data release.
The data is poor. Botched lab analysis shows less than 1% improvement. No proof that the 1% improvement translates to a clinical effect. The walk tests couldn't show a difference between historical controls either. The drug is as good as someone not taking it..that's why the FDA won't approve.
Thanks for letting us know that you don't know how to invest. We'll just have to ignore your advice on this one as well because you don't have any real arguments as to why this trial won't succeed.
If you work for Cohen and you are posting like this then you are at risk of market manipulation. It's obvious you are bashing to accumulate. Since why bother shorting a penny stock and lose everything. Just move on.